TD Asset Management Inc Grows Position in Hologic, Inc. $HOLX

TD Asset Management Inc grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 1.4% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,530,317 shares of the medical equipment provider’s stock after buying an additional 21,005 shares during the quarter. TD Asset Management Inc’s holdings in Hologic were worth $99,715,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of HOLX. Victory Capital Management Inc. boosted its position in Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after purchasing an additional 1,692,177 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Hologic by 473.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock worth $111,180,000 after purchasing an additional 1,405,085 shares in the last quarter. Nuance Investments LLC boosted its position in Hologic by 623.7% in the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock worth $66,794,000 after purchasing an additional 931,920 shares in the last quarter. Redwood Wealth Management Group LLC acquired a new position in shares of Hologic during the 1st quarter worth approximately $3,534,000. Finally, Invesco Ltd. lifted its position in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after buying an additional 764,573 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HOLX. Weiss Ratings reiterated a “hold (c-)” rating on shares of Hologic in a research report on Wednesday, October 8th. Mizuho set a $75.00 target price on Hologic in a research report on Thursday, July 31st. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Argus increased their target price on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Finally, Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $80.15.

Hologic Stock Up 0.6%

NASDAQ HOLX opened at $65.92 on Wednesday. The business has a fifty day moving average price of $67.06 and a 200 day moving average price of $63.38. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a market cap of $14.66 billion, a P/E ratio of 27.35, a P/E/G ratio of 2.25 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the company earned $1.06 EPS. The firm’s revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.